Patent 8957193 was granted and assigned to Apexigen on February, 2015 by the United States Patent and Trademark Office.
The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.